Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Investigators propose to develop hyperpolarized [13C]-labeled pyruvate as potential imaging probes to assess two essential in vivo processes in cerebral metabolism: oxidative metabolism and synthesis of a neurotransmitter.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Neurotransmitter Agents

Criteria

Inclusion Criteria:

• 18 through 60 years of age.

• Healthy, with no neurological abnormalities.

• Ability to understand and the willingness to sign a written informed consent.

• All races and ethnicities will be included; subjects must be able to read and speak the English or Spanish language.

Exclusion Criteria:

• Metallic foreign bodies on the scalp or cranium which may interfere with MRI acquisitions

• Major debilitating neurological disease including, but not limited to, stroke, CVA, dementia and tumor that would limit compliance with study requirements

• Under influence of illicit drugs which are known to alter brain physiology/metabolism including, but not limited to cocaine, lysergic acid diethylamide (LSD), and marijuana at the time of MRI/MRSI scanning.

• Under influence of antiepileptic drugs at the time of MRI/MRSI scanning.

• Any contraindication per MRI Screening Form including

• Implants contraindicated at 3T, pacemakers

• Implantable Cardioverter Defibrillator (ICD)

• Claustrophobia

• Medically unstable including

• Heart failure

• Severe left ventricular outflow tract (LVOT) obstruction

• Unstable angina

• Pregnancy

• Lactating